ExcelMale
Menu
Home
What's new
Latest activity
Forums
New posts
Search forums
What's new
New posts
Latest activity
Videos
Lab Tests
Doctor Finder
Buy Books
About Us
Men’s Health Coaching
Log in
Register
What's new
Search
Search
Search titles only
By:
New posts
Search forums
Menu
Log in
Register
Navigation
Install the app
Install
More options
Contact us
Close Menu
Forums
Testosterone Replacement, Low T, HCG, & Beyond
Testosterone and Men's Health Articles
Vascular Pathways of Testosterone: Clinical Implications
JavaScript is disabled. For a better experience, please enable JavaScript in your browser before proceeding.
You are using an out of date browser. It may not display this or other websites correctly.
You should upgrade or use an
alternative browser
.
Reply to thread
Message
<blockquote data-quote="madman" data-source="post: 165906" data-attributes="member: 13851"><p><strong><span style="color: rgb(184, 49, 47)">Abstract </span></strong></p><p></p><p>Cardiovascular diseases (CVD) are one of the leading causes of death worldwide. <strong><span style="color: rgb(184, 49, 47)">Testosterone (T) is an important sex hormone that triggers several genomic and non-genomic pathways, leading to improvements of several cardiovascular risk factors and quality of life in men.</span></strong> <strong><span style="color: rgb(44, 130, 201)">At the vascular level, the key effect of T is the vasorelaxation.</span> </strong><span style="color: rgb(44, 130, 201)"><strong>This review discusses the molecular pathways and clinical implications of T in the vascular system.</strong></span> Firstly, the mechanisms involved in the T vasodilator effect will be presented. Then, it will be discussed the association of T with the main risks for CVD, namely metabolic syndrome, type 2 diabetes mellitus, obesity, atherosclerosis, dyslipidaemia and hypertension. Several studies have shown a correlation between low T levels and an increased prevalence of several CVD. These observations suggest that T has beneficial effects on the cardiovascular system and that testosterone replacement therapy may become a therapeutic reality for some of these disorders</p><p></p><p></p><p></p><p></p><p></p><p></p><p></p><p></p><p><strong><span style="color: rgb(184, 49, 47)">Conclusions and Future Directions </span></strong></p><p></p><p>Cardiovascular diseases (CVD) are one of the leading causes of death worldwide. <span style="color: rgb(0, 0, 0)">The knowledge about the vascular effects of testosterone (T) is crucial to understand its clinical implications and may lead to new therapeutic targets in the future.</span><span style="color: rgb(184, 49, 47)"> <strong>Studies performed over the years agree that T is an important sex hormone that triggers several genomic and non-genomic pathways, leading to improvements of several cardiovascular risk factors and quality of life in men, contrary to what had been suggested at first instance.</strong></span> <span style="color: rgb(44, 130, 201)"><strong>T presents genomic and nongenomic actions at the vascular level, and both effects may overlap, which makes it difficult to define the broad vascular effects of androgens. However, the key T effect at the vascular level is the vasorelaxation, a non-genomic action (rapid effect). </strong></span></p><p></p><p><strong><span style="color: rgb(184, 49, 47)">Several studies have established a relationship between the low levels of T and an increase in the CVD prevalence, which seems to be mainly linked to the nongenomic actions of T, namely vasorelaxation. </span><span style="color: rgb(44, 130, 201)">This effect involves several mechanisms including the nuclear receptor activation, the influence of vascular endothelium and the activation or blocking of ion channels. So, the vasodilator mechanisms of T are crucial to understanding the relationship between the risk factors for CVD and this sex hormone.</span></strong></p><p></p><p>Several clinical and epidemiological studies observed that men with type 2 diabetes mellitus, obesity, metabolic syndrome, atherosclerosis, dyslipidaemia, and higher blood pressure had lower levels of T, suggesting a beneficial role of T on the cardiovascular system. Therefore, testosterone replacement therapy (TRT) could be a solution to improve these CVD risk factors. However, this issue has been the subject of controversy, as recent studies suggest that TRT is associated with an increase of CVD. Concerning type 2 diabetes mellitus and metabolic syndrome, most of the studies showed an association with low levels of T and that TRT improves these risk factors in men with hypogonadism. Regarding atherosclerosis and dyslipidaemia, low levels of T were also associated with an improvement of some parameters of these risk factors. Moreover, TRT seems to induce a more favourable lipid profile, contributing to increased protection for the development or progression of atherosclerosis. Regarding the association between T and blood pressure, few studies have been performed, but it seems that T is beneficial to diastolic and systolic blood pressure as well as the resting heart rate. Furthermore, excess or insufficient androgen production during pregnancy may trigger the development of preeclampsia or gestational hypertension. These studies also indicate that the administration of androgens in hypertensive pregnant women is a near possibility. Nevertheless, further clinical studies are needed.</p><p></p><p><span style="color: rgb(184, 49, 47)"><strong>In sum, the vascular effects of testosterone have clinical implications.</strong></span> However, a consensus on the T effects or the risks associated with TRT on the cardiovascular system needs to be established. <span style="color: rgb(44, 130, 201)"><strong>Considering the overlap between both genomic and non-genomic effects, and even a possible divergence in the effects of both actions, it is evidenced that a better understanding of the vascular mechanisms of testosterone is crucial.</strong></span> <span style="color: rgb(184, 49, 47)"><strong>Only then their clinical implications will be correctly established and the development of new therapeutic targets for cardiovascular diseases can be discovered.</strong></span></p></blockquote><p></p>
[QUOTE="madman, post: 165906, member: 13851"] [B][COLOR=rgb(184, 49, 47)]Abstract [/COLOR][/B] Cardiovascular diseases (CVD) are one of the leading causes of death worldwide. [B][COLOR=rgb(184, 49, 47)]Testosterone (T) is an important sex hormone that triggers several genomic and non-genomic pathways, leading to improvements of several cardiovascular risk factors and quality of life in men.[/COLOR][/B] [B][COLOR=rgb(44, 130, 201)]At the vascular level, the key effect of T is the vasorelaxation.[/COLOR] [/B][COLOR=rgb(44, 130, 201)][B]This review discusses the molecular pathways and clinical implications of T in the vascular system.[/B][/COLOR] Firstly, the mechanisms involved in the T vasodilator effect will be presented. Then, it will be discussed the association of T with the main risks for CVD, namely metabolic syndrome, type 2 diabetes mellitus, obesity, atherosclerosis, dyslipidaemia and hypertension. Several studies have shown a correlation between low T levels and an increased prevalence of several CVD. These observations suggest that T has beneficial effects on the cardiovascular system and that testosterone replacement therapy may become a therapeutic reality for some of these disorders [B][COLOR=rgb(184, 49, 47)]Conclusions and Future Directions [/COLOR][/B] Cardiovascular diseases (CVD) are one of the leading causes of death worldwide. [COLOR=rgb(0, 0, 0)]The knowledge about the vascular effects of testosterone (T) is crucial to understand its clinical implications and may lead to new therapeutic targets in the future.[/COLOR][COLOR=rgb(184, 49, 47)] [B]Studies performed over the years agree that T is an important sex hormone that triggers several genomic and non-genomic pathways, leading to improvements of several cardiovascular risk factors and quality of life in men, contrary to what had been suggested at first instance.[/B][/COLOR] [COLOR=rgb(44, 130, 201)][B]T presents genomic and nongenomic actions at the vascular level, and both effects may overlap, which makes it difficult to define the broad vascular effects of androgens. However, the key T effect at the vascular level is the vasorelaxation, a non-genomic action (rapid effect). [/B][/COLOR] [B][COLOR=rgb(184, 49, 47)]Several studies have established a relationship between the low levels of T and an increase in the CVD prevalence, which seems to be mainly linked to the nongenomic actions of T, namely vasorelaxation. [/COLOR][COLOR=rgb(44, 130, 201)]This effect involves several mechanisms including the nuclear receptor activation, the influence of vascular endothelium and the activation or blocking of ion channels. So, the vasodilator mechanisms of T are crucial to understanding the relationship between the risk factors for CVD and this sex hormone.[/COLOR][/B] Several clinical and epidemiological studies observed that men with type 2 diabetes mellitus, obesity, metabolic syndrome, atherosclerosis, dyslipidaemia, and higher blood pressure had lower levels of T, suggesting a beneficial role of T on the cardiovascular system. Therefore, testosterone replacement therapy (TRT) could be a solution to improve these CVD risk factors. However, this issue has been the subject of controversy, as recent studies suggest that TRT is associated with an increase of CVD. Concerning type 2 diabetes mellitus and metabolic syndrome, most of the studies showed an association with low levels of T and that TRT improves these risk factors in men with hypogonadism. Regarding atherosclerosis and dyslipidaemia, low levels of T were also associated with an improvement of some parameters of these risk factors. Moreover, TRT seems to induce a more favourable lipid profile, contributing to increased protection for the development or progression of atherosclerosis. Regarding the association between T and blood pressure, few studies have been performed, but it seems that T is beneficial to diastolic and systolic blood pressure as well as the resting heart rate. Furthermore, excess or insufficient androgen production during pregnancy may trigger the development of preeclampsia or gestational hypertension. These studies also indicate that the administration of androgens in hypertensive pregnant women is a near possibility. Nevertheless, further clinical studies are needed. [COLOR=rgb(184, 49, 47)][B]In sum, the vascular effects of testosterone have clinical implications.[/B][/COLOR] However, a consensus on the T effects or the risks associated with TRT on the cardiovascular system needs to be established. [COLOR=rgb(44, 130, 201)][B]Considering the overlap between both genomic and non-genomic effects, and even a possible divergence in the effects of both actions, it is evidenced that a better understanding of the vascular mechanisms of testosterone is crucial.[/B][/COLOR] [COLOR=rgb(184, 49, 47)][B]Only then their clinical implications will be correctly established and the development of new therapeutic targets for cardiovascular diseases can be discovered.[/B][/COLOR] [/QUOTE]
Insert quotes…
Verification
Post reply
Share this page
Facebook
Twitter
Reddit
Pinterest
Tumblr
WhatsApp
Email
Share
Link
Sponsors
Forums
Testosterone Replacement, Low T, HCG, & Beyond
Testosterone and Men's Health Articles
Vascular Pathways of Testosterone: Clinical Implications
This site uses cookies to help personalise content, tailor your experience and to keep you logged in if you register.
By continuing to use this site, you are consenting to our use of cookies.
Accept
Learn more…
Top